FFA
BBIO icon

Farther Finance Advisors’s BridgeBio Pharma BBIO Stock Holding History

Farther Finance Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$69.9K Sell
1,062
-181
-15% -$14.1K ﹤0.01% 3146
2026
Q2 		$91.8K Sell
1,243
-230
-16% -$16.1K ﹤0.01% 2770
2026
Q1 		$110K Buy
1,473
+960
+187% +$69.6K ﹤0.01% 2446
2025
Q4 		$39.2K Buy
513
+245
+91% +$16.1K ﹤0.01% 2976
2025
Q3 		$13.9K Buy
268
+58
+28% +$2.83K ﹤0.01% 3260
2025
Q2 		$9.07K Sell
210
-14
-6% -$509 ﹤0.01% 3122
2025
Q1 		$7.4K Buy
224
+24
+12% +$809 ﹤0.01% 2877
2024
Q4 		$5.49K Buy
200
+63
+46% +$1.63K ﹤0.01% 2628
2024
Q3 		$3.47K Buy
137
+41
+43% +$1.08K ﹤0.01% 2795
2024
Q2 		$2.42K Buy
96
+5
+5% +$137 ﹤0.01% 2715
2024
Q1 		$2.73K Sell
91
-5
-5% -$170 ﹤0.01% 2360
2023
Q4 		$3.88K Buy
96
+91
+1,820% +$2.73K ﹤0.01% 2098
2023
Q3 		$132 Buy
+5
New +$142 ﹤0.01% 2525

Other funds holding BBIO

CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GWM
GK Wealth Management Reno, Nevada $178M AUM 41.48% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return
MAM
Marquette Asset Management Minneapolis, Minnesota $766M AUM 16.04% 1-Year Est. Return
PS
Planning Strategies Lancaster, Pennsylvania $169M AUM
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Farther Finance Advisors's BBIO Position: Q3 2026 in Review

Farther Finance Advisors reduced its BridgeBio Pharma (BBIO) stake by 15% in Q3 2026, selling an estimated $14.1K and leaving 1,062 shares worth $69.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3146.

Farther Finance Advisors first reported a position in BBIO in Q3 2023 and has held it in 13 quarters since. The position peaked at $110K in Q1 2026. 12 funds tracked by Wall St. Rank hold BBIO as of Q3 2026.

  • Farther Finance Advisors held 1,062 shares of BridgeBio Pharma worth $69.9K as of Q3 2026.
  • Farther Finance Advisors sold 181 BridgeBio Pharma shares in Q3 2026, an estimated $14.1K.
  • BridgeBio Pharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #3146 holding.
  • Farther Finance Advisors first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 13 quarters since.
  • Farther Finance Advisors's BridgeBio Pharma position peaked at $110K in Q1 2026.
  • 12 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.